Global Preclinical Drug Development Services 麻豆原创 Research Report 2025

Publication ID:

PB503252073

Publication Date:

March 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Preclinical Drug Development Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Preclinical Drug Development Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preclinical Drug Development Services.
The Preclinical Drug Development Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Preclinical Drug Development Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Preclinical Drug Development Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Wuxi AppTec
Labcorp
Charles River
Eurofins Scientific
PPD, Inc.
ICON Plc.
Pharmaron
Inotiv
ChemPartner
JOINN Lab
EVOTEC
Medicilon
Noble Life Sciences
Segment by Type
API Preparation
Formulation Studies
Safety Studies
ADME Stuies
Segment by Application
Pharmaceutical
Bio-pharmaceutical
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Preclinical Drug Development Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Preclinical Drug Development Services 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 API Preparation
1.2.3 Formulation Studies
1.2.4 Safety Studies
1.2.5 ADME Stuies
1.3 麻豆原创 by Application
1.3.1 Global Preclinical Drug Development Services 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical
1.3.3 Bio-pharmaceutical
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Preclinical Drug Development Services 麻豆原创 Perspective (2020-2031)
2.2 Global Preclinical Drug Development Services Growth Trends by Region
2.2.1 Global Preclinical Drug Development Services 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Preclinical Drug Development Services Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Preclinical Drug Development Services Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Preclinical Drug Development Services 麻豆原创 Dynamics
2.3.1 Preclinical Drug Development Services Industry Trends
2.3.2 Preclinical Drug Development Services 麻豆原创 Drivers
2.3.3 Preclinical Drug Development Services 麻豆原创 Challenges
2.3.4 Preclinical Drug Development Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Preclinical Drug Development Services Players by Revenue
3.1.1 Global Top Preclinical Drug Development Services Players by Revenue (2020-2025)
3.1.2 Global Preclinical Drug Development Services Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Preclinical Drug Development Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Preclinical Drug Development Services Revenue
3.4 Global Preclinical Drug Development Services 麻豆原创 Concentration Ratio
3.4.1 Global Preclinical Drug Development Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Preclinical Drug Development Services Revenue in 2024
3.5 Global Key Players of Preclinical Drug Development Services Head office and Area Served
3.6 Global Key Players of Preclinical Drug Development Services, Product and Application
3.7 Global Key Players of Preclinical Drug Development Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Preclinical Drug Development Services Breakdown Data by Type
4.1 Global Preclinical Drug Development Services Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Preclinical Drug Development Services Forecasted 麻豆原创 Size by Type (2026-2031)
5 Preclinical Drug Development Services Breakdown Data by Application
5.1 Global Preclinical Drug Development Services Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Preclinical Drug Development Services Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Preclinical Drug Development Services 麻豆原创 Size (2020-2031)
6.2 North America Preclinical Drug Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Preclinical Drug Development Services 麻豆原创 Size by Country (2020-2025)
6.4 North America Preclinical Drug Development Services 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Preclinical Drug Development Services 麻豆原创 Size (2020-2031)
7.2 Europe Preclinical Drug Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Preclinical Drug Development Services 麻豆原创 Size by Country (2020-2025)
7.4 Europe Preclinical Drug Development Services 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Preclinical Drug Development Services 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Preclinical Drug Development Services 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Preclinical Drug Development Services 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Preclinical Drug Development Services 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Preclinical Drug Development Services 麻豆原创 Size (2020-2031)
9.2 Latin America Preclinical Drug Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Preclinical Drug Development Services 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Preclinical Drug Development Services 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Preclinical Drug Development Services 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Preclinical Drug Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Preclinical Drug Development Services 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Preclinical Drug Development Services 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Wuxi AppTec
11.1.1 Wuxi AppTec Company Details
11.1.2 Wuxi AppTec Business Overview
11.1.3 Wuxi AppTec Preclinical Drug Development Services Introduction
11.1.4 Wuxi AppTec Revenue in Preclinical Drug Development Services Business (2020-2025)
11.1.5 Wuxi AppTec Recent Development
11.2 Labcorp
11.2.1 Labcorp Company Details
11.2.2 Labcorp Business Overview
11.2.3 Labcorp Preclinical Drug Development Services Introduction
11.2.4 Labcorp Revenue in Preclinical Drug Development Services Business (2020-2025)
11.2.5 Labcorp Recent Development
11.3 Charles River
11.3.1 Charles River Company Details
11.3.2 Charles River Business Overview
11.3.3 Charles River Preclinical Drug Development Services Introduction
11.3.4 Charles River Revenue in Preclinical Drug Development Services Business (2020-2025)
11.3.5 Charles River Recent Development
11.4 Eurofins Scientific
11.4.1 Eurofins Scientific Company Details
11.4.2 Eurofins Scientific Business Overview
11.4.3 Eurofins Scientific Preclinical Drug Development Services Introduction
11.4.4 Eurofins Scientific Revenue in Preclinical Drug Development Services Business (2020-2025)
11.4.5 Eurofins Scientific Recent Development
11.5 PPD, Inc.
11.5.1 PPD, Inc. Company Details
11.5.2 PPD, Inc. Business Overview
11.5.3 PPD, Inc. Preclinical Drug Development Services Introduction
11.5.4 PPD, Inc. Revenue in Preclinical Drug Development Services Business (2020-2025)
11.5.5 PPD, Inc. Recent Development
11.6 ICON Plc.
11.6.1 ICON Plc. Company Details
11.6.2 ICON Plc. Business Overview
11.6.3 ICON Plc. Preclinical Drug Development Services Introduction
11.6.4 ICON Plc. Revenue in Preclinical Drug Development Services Business (2020-2025)
11.6.5 ICON Plc. Recent Development
11.7 Pharmaron
11.7.1 Pharmaron Company Details
11.7.2 Pharmaron Business Overview
11.7.3 Pharmaron Preclinical Drug Development Services Introduction
11.7.4 Pharmaron Revenue in Preclinical Drug Development Services Business (2020-2025)
11.7.5 Pharmaron Recent Development
11.8 Inotiv
11.8.1 Inotiv Company Details
11.8.2 Inotiv Business Overview
11.8.3 Inotiv Preclinical Drug Development Services Introduction
11.8.4 Inotiv Revenue in Preclinical Drug Development Services Business (2020-2025)
11.8.5 Inotiv Recent Development
11.9 ChemPartner
11.9.1 ChemPartner Company Details
11.9.2 ChemPartner Business Overview
11.9.3 ChemPartner Preclinical Drug Development Services Introduction
11.9.4 ChemPartner Revenue in Preclinical Drug Development Services Business (2020-2025)
11.9.5 ChemPartner Recent Development
11.10 JOINN Lab
11.10.1 JOINN Lab Company Details
11.10.2 JOINN Lab Business Overview
11.10.3 JOINN Lab Preclinical Drug Development Services Introduction
11.10.4 JOINN Lab Revenue in Preclinical Drug Development Services Business (2020-2025)
11.10.5 JOINN Lab Recent Development
11.11 EVOTEC
11.11.1 EVOTEC Company Details
11.11.2 EVOTEC Business Overview
11.11.3 EVOTEC Preclinical Drug Development Services Introduction
11.11.4 EVOTEC Revenue in Preclinical Drug Development Services Business (2020-2025)
11.11.5 EVOTEC Recent Development
11.12 Medicilon
11.12.1 Medicilon Company Details
11.12.2 Medicilon Business Overview
11.12.3 Medicilon Preclinical Drug Development Services Introduction
11.12.4 Medicilon Revenue in Preclinical Drug Development Services Business (2020-2025)
11.12.5 Medicilon Recent Development
11.13 Noble Life Sciences
11.13.1 Noble Life Sciences Company Details
11.13.2 Noble Life Sciences Business Overview
11.13.3 Noble Life Sciences Preclinical Drug Development Services Introduction
11.13.4 Noble Life Sciences Revenue in Preclinical Drug Development Services Business (2020-2025)
11.13.5 Noble Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Wuxi AppTec
Labcorp
Charles River
Eurofins Scientific
PPD, Inc.
ICON Plc.
Pharmaron
Inotiv
ChemPartner
JOINN Lab
EVOTEC
Medicilon
Noble Life Sciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.